Keyphrases
Venous Thromboembolism
81%
Multiple Myeloma
68%
Anticoagulation
34%
Thromboprophylaxis
33%
American Society of Hematology
24%
United States Veterans
24%
Thrombosis
23%
Direct Oral Anticoagulants
22%
Patients with COVID-19
22%
Confidence Interval
21%
Living Guidelines
20%
Apixaban
19%
Hemostasis
18%
Diffuse Large B-cell Lymphoma (DLBCL)
18%
In Cancer
17%
Bleeding
17%
Enzalutamide
16%
Abiraterone
16%
Cancer-associated Venous Thromboembolism
15%
Monoclonal Gammopathy of Undetermined Significance
15%
Malignancy
15%
Patients with Cancer
13%
Coronavirus Disease (COVID)
13%
Retrospective Cohort Study
13%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
12%
Chemotherapy
11%
COVID-19
11%
Warfarin
11%
Dose Reduction
11%
Venous Thromboembolism Risk
10%
Anticoagulants
10%
Body Mass Index
10%
High Risk
9%
Overall Survival
9%
Grading of Recommendations
9%
Evaluation Assessment
9%
Assessment Development
9%
Critical Illness
9%
Hematological Malignancies
9%
Hospitalization
9%
Secondary Prevention
9%
Cancer Patients
9%
Comorbid Diseases
9%
Major Bleeding
9%
Comparative Effectiveness
9%
Venous Thromboembolism Treatment
8%
Frailty
8%
US Veterans
8%
Cancer-associated Thrombosis
8%
Statins
8%
Medicine and Dentistry
Venous Thromboembolism
100%
Multiple Myeloma
48%
COVID-19
37%
Thrombosis
36%
Anticoagulation
35%
Thromboprophylaxis
33%
Malignant Neoplasm
24%
Hematology
24%
Bleeding
21%
Clinician
19%
Blood Stasis
18%
Direct Oral Anticoagulant
17%
Apixaban
16%
Cancer
14%
Hematologic Malignancy
13%
Diffuse Large B-Cell Lymphoma
12%
Odds Ratio
10%
Cancer Treatment
9%
Antithrombotic
9%
Drug Dose Reduction
9%
Critical Illness
9%
Hazard Ratio
9%
Major Bleeding
9%
Retrospective Cohort Study
9%
Secondary Prevention
8%
Thrombocytopenia
8%
CHOP
8%
Pancreas Cancer
8%
Sarcopenia
8%
Monoclonal Gammopathy of Undetermined Significance
8%
Myeloma
8%
Acute Disease
7%
Diseases
6%
Randomized Controlled Trial
6%
Anticoagulant Therapy
6%
International Classification of Diseases
5%
Overall Survival
5%
Body Mass Index
5%
Risk Stratification
5%
Lenalidomide
5%
Rivaroxaban
5%
Low Molecular Weight Heparin
5%
Health Care
5%
Health Outcomes
5%
Dexamethasone
5%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
56%
Multiple Myeloma
48%
Thrombosis
22%
Malignant Neoplasm
18%
Chemotherapy
18%
Bleeding
16%
Enzalutamide
16%
Abiraterone
16%
Cohort Study
13%
Diffuse Large B Cell Lymphoma
13%
Direct Oral Anticoagulant
13%
Diseases
12%
Warfarin
12%
Prostate Cancer
12%
Monoclonal Immunoglobulinemia
11%
Apixaban
10%
Hematologic Malignancy
8%
Frailty
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Myeloma
8%
Overall Survival
6%
Lenalidomide
5%
Anticoagulant Agent
5%
Dexamethasone
5%